SeaStar Medical Announces That Stanford Medicine Is Cleared To Actively Enroll Subjects In The NEUTRALIZE-AKI Adult Acute Kidney Injury Pivotal Trial
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical Holding Corporation (NASDAQ:ICU) has announced that Stanford Medicine is cleared to enroll subjects in the NEUTRALIZE-AKI pivotal trial for adult acute kidney injury. This trial now includes 12 sites with 52 subjects enrolled.
October 23, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical's NEUTRALIZE-AKI trial for acute kidney injury is expanding with Stanford Medicine's clearance to enroll subjects, now totaling 12 sites and 52 subjects.
The clearance for Stanford Medicine to enroll subjects in the NEUTRALIZE-AKI trial is a positive development for SeaStar Medical, indicating progress in their clinical trials. This expansion to 12 sites and 52 subjects suggests increased research activity and potential advancements in their medical solutions, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100